Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Next Previous
Search
Trial Profile

A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IOV-4001 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Iovance Biotherapeutics

    • Most Recent Events

    • 09 May 2024 According to a Iovance Biotherapeutics media release, Phase 1 safety portion concluded in the first in human IOV-GM1-201 trial and the trial is progressing successfully into the multi-center Phase 2 efficacy stage. Iovance continues to utilize the TALEN technology licensed from Cellectis to develop other investigational gene-edited TIL cell therapies with multiple knockout targets to improve efficacy.
    • 10 Oct 2022 According to a Iovance Biotherapeutics media release, first patient has been dosed in this trial.
    • 05 Oct 2022 According to a Iovance Biotherapeutics media release, trial-in-Progress data will be presented at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top